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PPrognostic Implications of Baroreflex Sensitivity
in Heart Failure Patients in the Beta-Blocking Era
Maria Teresa La Rovere, MD,* Gian Domenico Pinna, MS,* Roberto Maestri, MS,* Elena Robbi, BS,*
Angelo Caporotondi, MD,* Gianpaolo Guazzotti, MD,* Peter Sleight, MD, DM,† Oreste Febo, MD*
Montescano, Italy; and Oxford, United Kingdom
Objectives This study investigated the clinical correlates and prognostic value of depressed baroreceptor-heart rate reflex
sensitivity (BRS) among patients with heart failure (HF), with and without beta-blockade.
Background Abnormalities in autonomic reflexes play an important role in the development and progression of HF. Few stud-
ies have assessed the effects of beta-blockers on BRS in HF.
Methods The study population consisted of 103 stable HF patients, age (median [interquartile range]) 54 years (48 to 57 years), with
New York Heart Association (NYHA) functional classIII in 22, and with a left ventricular ejection fraction (LVEF) of 30%
(24% to 36%), treated with beta-blockers; and 144 untreated patients, age 55 years (48 to 60 years), with NYHA functional
classIII in 47%, and an LVEF of 26% (21% to 30%). They underwent BRS testing (phenylephrine technique).
Results In both treated and untreated patients, a lower BRS was associated with a higher (III) NYHA functional class
(p  0.0002 and p  0.0001, respectively); a more severe (2) mitral regurgitation (p  0.007 and p 
0.0002), respectively; a lower LVEF (p  0.0004 and p  0.001, respectively), baseline RR interval (p  0.0004
and p  0.0002, respectively), and SDNN (p  0.0001, p  0.002, respectively); and a higher blood urea nitro-
gen (p  0.004, p  0.0001, respectively). Clinical variables explained only 43% of BRS variability among treated
and 36% among untreated patients. During a median follow-up of 29 months, 17 of 103 patients and 55 of 144 pa-
tients, respectively, experienced a cardiac event. A depressed BRS (3.0 ms/mm Hg) was significantly associated
with the outcome, independently of known risk predictors and beta-blocker treatment (adjusted hazard ratio: 3.0
[95% confidence interval: 1.5 to 5.9], p  0.001).
Conclusions Baroreceptor-heart rate reflex sensitivity does not simply mirror the pathophysiological substrate of HF. A de-
pressed BRS conveys independent prognostic information that is not affected by the modification of autonomic
dysfunction brought about by beta-blockade. (J Am Coll Cardiol 2009;53:193–9) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.034T
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ln impairment of baroreflex control of heart rate is a promi-
ent characteristic of the heart failure (HF) syndrome (1).
lthough in the traditional pathophysiological model of HF,
agal withdrawal and sympathetic activation are initiated by
he arterial baroreflex, a cause-and-effect relationship between
aroreflex dysfunction and increased sympathetic activity has
ot been established. Other possible mediators include
ympatho-excitatory reflexes and humoral factors. Recent evi-
ence suggests that central mechanisms that rely on angioten-
in II and nitric oxide might play a pivotal role (2).
We and others (3–5) found that reduced baroreceptor-heart
ate reflex sensitivity (BRS) in HF patients is a powerful and
ndependent predictor of prognosis in multivariate analysis.
rom the *Divisione di Cardiologia, e Bioingegneria, Fondazione “Salvatore
augeri,” IRCCS Istituto Scientifico di Montescano, Montescano, Italy; and the
Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford,
xford, United Kingdom.r
Manuscript received July 11, 2008; revised manuscript received August 28, 2008,
ccepted September 1, 2008.hese data were mainly obtained at a time when the use of
eta-blockade in HF was very uncommon. The observed
ortality benefits of long-term beta-blockade in HF are largely
ased on antiadrenergic effects that do not alter the underlying
bnormalities of control but rather mitigate the end-organ
esults of disordered control (6). Few studies have assessed the
ffects of beta-blockade on BRS in HF patients (7,8).
We therefore thought that it would be of interest to
e-examine whether the more widespread use of beta-blockers
n HF might affect the prognostic value of BRS testing. The
ossibility might exist that the prognostic value of BRS could
e less following the reversal of autonomic dysfunction and
lower heart rate brought about by beta-blockade. Thus, we
lanned a retrospective analysis of our prospectively collected
atabase to evaluate the clinical correlates and outcome of BRS
n patients treated by beta-blockade (for at least 3 months) and
ho continued receiving beta-blockers thereafter during pro-
onged follow-up, as compared with patients who were not
eceiving beta-blockade.
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Study patients. Of 471 patients
in sinus rhythm and moderate-
to-severe HF consecutively re-
ferred to our HF unit from Jan-
uary 1996 to August 2002, 349
were in stable clinical condition
and receiving optimal therapy.
Sixty-two patients were excluded
because of incomplete clinical
data. Of the remaining patients,
103 were and 144 were not re-
ceiving beta-blockers at the time
of BRS assessment and contin-
ued thereafter during follow-up.
Forty subjects were excluded be-
cause they were under beta-
blocker titration at the time of
BRS assessment or because they
began the treatment after the
test. This led to a final sample of
247 cases available for the study.
All patients gave written in-
formed consent, and the study was
approved by the local Ethics
Committee.
Methods and follow-up. Baro-
receptor-heart rate reflex sensitivity
was assessed by the phenylephrine
test as previously described (9).
Within 1 week from the autonomic
evaluation, standard clinical and lab-
ratory examinations, including 2-dimensional echocardiography,
ardiopulmonary exercise testing, 24-h Holter recording, and
outine blood tests, were performed. During follow-up, pa-
ients were periodically re-evaluated and hospitalized if
linically unstable. The date and mode of death, as well as
nformation regarding transplantation, were accurately
nvestigated.
tatistical analysis. Comparisons between groups were
erformed by the ANOVA, Mann-Whitney U test, or
hi-square test when appropriate. The correlation between
RS and continuous variables was assessed by Spearman
ank-correlation coefficient.
To assess the association between BRS (considered a
ependent variable) and clinical variables (considered ex-
lanatory variables), we carried out a multiple regression
nalysis in treated and untreated patients separately. Because
f their skewed distribution, BRS measurements were log-
ransformed. Nonsignificant variables were eliminated by a
ackward elimination procedure at the 0.15 significance level.
The end point of survival analysis was total cardiac
eath, including appropriate and documented implant-
ble cardioverter-defibrillator (ICD) discharge, or urgent
Abbreviations
and Acronyms
BRS  baroreceptor-heart
rate reflex sensitivity
BUN  blood urea nitrogen
CI  confidence interval
CNES  cardiac
norepinephrine spillover
HF  heart failure
ICD  implantable
cardioverter-defibrillator
IQR  interquartile range
LVEDD  left ventricular
end-diastolic diameter
LVEF  left ventricular
ejection fraction
LVESD  left ventricular
end-systolic diameter
MSNA  muscle
sympathetic nerve activity
NSVT  nonsustained
ventricular tachycardia
NYHA  New York Heart
Association
SAP  systolic arterial
pressure
SDNN  standard deviation
of all normal-to-normal
intervals
VPC  ventricular
premature contractionransplantation. tSurvival analysis was carried out by merging the 2 groups
f patients. The BRS was dichotomized according to the
re-selected cutoff value of 3 ms/mm Hg, which has been
sed in most previous studies on the prognostic significance
f BRS in cardiac disease patients (9).
A Cox proportional hazards prognostic model based on
nown risk factors was developed considering as potential
redictors age, ischemic cardiomyopathy, New York Heart
ssociation (NYHA) functional class, systolic arterial pres-
ure (SAP), left ventricular ejection fraction (LVEF), left
entricular end-diastolic diameter (LVEDD), blood urea
itrogen (BUN), serum sodium, peak VO2, standard devi-
tion of all normal-to-normal intervals (SDNN), ventricular
rrhythmias on 24-h Holter recordings, and beta-blocker
herapy (yes/no). Less predictive variables were eliminated
y a backward elimination procedure at the 0.15 significance
evel. The BRS was then entered in the selected model
ogether with a beta-blocker treatment-by-BRS interaction
erm to test whether the relationship between BRS and
ortality changed between treated and untreated subjects.
Survival curves were estimated by the Kaplan-Meier
ethod and compared by the log-rank test.
Descriptive statistics are given as median and interquar-
ile range (IQR). All analyses were performed using the
AS/STAT statistical package, release 8.02 (SAS Institute,
ary, North Carolina).
esults
emographic and clinical characteristics of the 103 treated
nd 144 untreated patients are given in Table 1. The BRS
as more than double in treated patients: 5.1 (IQR 2.1 to
0) ms/mm Hg versus 2.0 (IQR 0.5 to 5.0) ms/mm Hg
p  0.0001).
linical correlates of BRS. The correlation of BRS with
linical variables was very similar in both treated and untreated
atients. Indeed, BRS was significantly depressed in patients
ith higher NYHA functional class and more severe mitral
egurgitation, whereas no difference was observed according to
he underlying etiology or the presence of nonsustained ven-
ricular tachycardia (NSVT) (Table 2). Although highly sig-
ificant, weak-to-modest correlations were observed be-
ween BRS and LVEF, SDNN, ventricular premature
ontractions (VPCs), baseline RR interval, and BUN (rs 
.34, p  0.0004; rs  0.52, p  0.0001; rs  0.22, p 
.02; rs 0.34, p 0.0004; rs0.28, p 0.004) among
reated patients. Similar values were also found for un-
reated patients except for VPCs (rs 0.27, p 0.001; rs
.26, p  0.002; rs  0.09, p  0.27; rs  0.30, p 
.0002; rs  0.42, p  0.0001).
Thirty-two (31%) of the treated patients and 92 (64%) of
he untreated patients had depressed BRS (i.e., 3 ms/mm
g). Table 3 compares the demographic and clinical char-
cteristics of both treated and untreated patients according
o BRS categorization. In both groups, patients with de-
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January 13, 2009:193–9 Baroreceptors and Beta-Blockers in HFressed BRS had more severely compromised clinical and
aboratory data, except for the incidence of NSVT.
When multiple regression analysis was carried out to
ssess the association between BRS and clinical variables
mong treated patients, we found that LVEDD, baseline
R interval, peak VO2, SDNN, VPCs, BUN, and serum
odium were significant and independent predictors (Table 4),
ccounting for 43% of BRS variability. All other variables
ere largely nonsignificant (p  0.28). The model for
ntreated patients is reported in the same Table 4. For these
atients, significant predictors were NYHA functional class,
VEDD, baseline RR interval, VPCs, BUN, serum potas-
ium, and NSVT, accounting for 36% of BRS variability.
rognostic value of BRS. During a median follow-up of
9 months (range 0.4 to 60 months), 17 treated patients
17%) experienced a cardiac event (including 1 urgent
ransplantation and 1 ICD discharge), whereas the event
Demographic, Clinical, and Functional Charactein Treated (Beta-Blocker) and Untre ted (No B
Table 1 Demographic, Clinical, and Functionin Treated (Beta-Blocker) and Untre
Characteristic
Beta-Blo
(n
Age (yrs) 54 (
Sex (% men)
NYHA functional class (%)
I–II
III–IV
Cause of HF (%)
Ischemic
Nonischemic
Baseline RR interval (ms) 867 (
Resting systolic arterial pressure (mm Hg) 115 (
Resting diastolic arterial pressure (mm Hg) 70 (
LVEF (%) 30 (
LVESD (mm) 57 (
LVEDD (mm) 68 (
Mitral regurgitation 2–3 (%)
Peak VO2 (ml/kg/min) 16 (
VPCs (n/h) 11 (
NSVT (%)
SDNN (ms) 101 (
BUN (mg/dl) 47 (
Creatinine (mg/dl) 1.14 (
Sodium (mEq/l) 141 (
Potassium (mEq/l) 4.4 (
Bilirubin (mg/dl) 0.69 (
BRS (ms/mm Hg) 5.1 (
Medical therapy (%)
ACE inhibitors
Diuretics
Nitrates
Digitalis
Amiodarone
Continuous variables are expressed as median (lower quartile–upper
ACE angiotensin-converting enzyme; BRS baroreceptor-heart ra
left ventricular end-diastolic diameter; LVEF left ventricular ejection f
ventricular tachycardia; NYHA New York Heart Association; SDNN sta
contraction.ate rose to 38% (55 of 144, including 6 urgent transplan- sations and 3 ICD discharges) among untreated patients.
ero noncardiac deaths and 6 elective transplantations
ccurred in treated patients, whereas these figures were 5
nd 24, respectively, among untreated patients.
The BRS was markedly lower in the patients with a worse
utcome: median 2.0 ms/mm Hg (IQR 0.3 to 4.0) versus
.0 ms/mm Hg (IQR 3.1 to 10) (p  0.003) for treated
atients and 1.6 ms/mm Hg (IQR 0.5 to 3.0) versus 2.3
s/mm Hg (IQR 0.7 to 6.5) (p  0.023) for untreated
atients. Among treated patients, the 5-year death rate was
3% (95% confidence interval [CI]: 29% to 78%) among
atients with a BRS 3 ms/mm Hg, lowering to 14% (95%
I: 2% to 25%) among patients with a more preserved BRS
p  0.0001). In untreated patients, the death rate was 82%
95% CI: 67% to 97%) among patients with depressed BRS
nd 42% (95% CI: 23% to 61%) among patients with a more
reserved BRS (p  0.0001). Corresponding Kaplan-Meier
socker) Patients
haracteristics
(No Beta-Blocker) Patients
atients
)
No Beta-Blocker Patients
(n  144) p Value
) 55 (48–60) 0.25
87
53 0.0001
47
56 0.07
44
35) 792 (708–890) 0.0001
30) 110 (100–120) 0.005
) 70 (70–80) 0.06
) 26 (21–30) 0.0001
) 60 (52–67) 0.002
) 70 (66–78) 0.017
33 0.06
) 14 (12–17) 0.0001
20 (5–82) 0.017
44 0.02
4) 81 (57–108) .0001
) 50 (41–58) 0.12
.28) 1.17 (1.03–1.34) 0.09
42) 140 (138–142) 0.002
6) 4.4 (4.2–4.7) 0.28
.83) 0.77 (0.53–1.13) 0.04
) 2.0 (0.5–5.0) 0.0001
84 0.46
88 0.52
58 0.07
63 0.001
37 0.0001
).
x sensitivity; BUN blood urea nitrogen; HF heart failure; LVEDD
; LVESD left ventricular end-systolic diameter; NSVT nonsustained
eviation of normal-to-normal RR intervals; VPC ventricular prematureristicta-Bl
al C
ated
cker P
 103
48–57
82
78
22
44
56
789–9
110–1
70–80
24–36
49–63
62–73
22
14–20
2–40)
29
76–12
38–53
0.95–1
139–1
4.1–4.
0.54–0
2.1–10
87
85
47
43
14
quartile
te refle
ractionurvival curves are shown in Figure 1.
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Baroreceptors and Beta-Blockers in HF January 13, 2009:193–9Table 5 shows the characteristics of surviving (n  175)
nd deceased (n  72) patients in the entire population.
he patients who died were older and had higher NYHA
unctional class, reduced peak VO2, and worse LV function
nd blood chemistry.
Among clinical variables, NYHA functional class,
VEDD, BUN, and beta-blocker treatment were identified
s those with the highest joint predictive value (p  0.01,
 0.0001, p  0.003, and p  0.0001, respectively). All
ther variables were nonsignificant (p 0.28). Taken alone,
BRS 3 ms/mm Hg showed a highly significant associ-
tion with an increased risk of cardiac death with a hazard
atio of 5.2 (95% CI: 3.1 to 8.99) (p  0.0001). When BRS
Clinical Correlates of BRS Measurements in Tre
Table 2 Clinical Correlates of BRS Measure
Beta-Blocker BRS
(ms/mm Hg) (n  103)
Etiology
Ischemic 5.0 (2.0–9.0)
Idiopathic 5.7 (3.1–10.0)
NYHA functional class
I–II 6.4 (3.5–11.2)
III–IV 2.0 (0.5–5.0)
Mitral regurgitation
0–1 5.9 (3.4–10.0)
2–3 2.0 (1.2–7.7)
NSVT
No 5.8 (3.0–10.0)
Yes 3.3 (1.5–9.0)
Abbreviations as in Table 1.
emographic, Clinical, and Functional Characteristics Accordingo BRS <3 or >3 ms/mm Hg in Patients Treated and Untreated W
Table 3 Demographic, Clinical, and Functional Characteristicsto BRS <3 or >3 ms/mm Hg in Patients Treated and
Treated With Beta-Blocke
BRS <3 ms/mm Hg (n  32) BRS >3 m
Age (yrs) 55 (52–61) 5
NYHA functional class III (%) 47
Ischemic etiology (%) 56
Baseline RR interval (ms) 861 (752–943) 98
Systolic arterial pressure (mm Hg) 110 (100–120) 11
Diastolic arterial pressure (mm Hg) 70 (70–80)
LVEF (%) 26 (22–30) 3
LVESD (mm) 61 (54–68) 5
LVEDD (mm) 70 (66–80) 6
Mitral regurgitation 2–3 (%) 47
Peak VO2 (ml/kg/min) 15 (12–17) 1
VPCs (n/h) 16 (5–41)
NSVT (%) 44
SDNN (ms) 79 (69–97) 11
BUN (mg/dl) 51 (47–66) 4
Creatinine (mg/dl) 1.2 (1.11–1.41) 1.
Sodium (mEq/l) 141 (139–142) 1
Potassium (mEq/l) 4.4 (4.2–4.7) 4
Bilirubin (mg/dl) 0.74 (0.62–0.97) 0.
BRS (ms/mm Hg) 1.2 (0.2–2.0) 7.ata are expressed as median (lower quartile–upper quartile). *p  0.05, †p  0.0001, ‡p  0.001, §p
Abbreviations as in Table 1.as entered into the clinical model, a significant association
ith the outcome was maintained with a hazard ratio of 3.0
95% CI: 1.5 to 5.9) (p  0.001). As shown in the final
odel results of Table 6, the interaction between beta-
locker treatment and BRS was nonsignificant, suggesting
hat the predictive value of BRS did not change between
reated and untreated subjects.
iscussion
his study shows that an impaired baroreflex plays an
mportant role in the prediction of outcomes in HF patients
ven in the presence of beta-blockade, thus suggesting that
and Untreated Patients
s in Treated and Untreated Patients
Value
No Beta-Blocker BRS
(ms/mm Hg) (n  144) p Value
.55 1.7 (0.6–5.0) 0.53
2.2 (0.4–5.0)
.0002 4.3 (1.7–7.9) 0.0001
1.7 (0.1–2.0)
.007 2.5 (1.0–6.5) 0.0002
0.8 (0.0–2.5)
.10 2.0 (0.5–4.2) 0.23
2.2 (0.5–6.1)
eta-Blockers
rding
ated With Beta-Blockers
Untreated With Beta-Blockers
Hg (n  71) BRS <3 ms/mm Hg (n  92) BRS >3 ms/mm Hg (n  52)
–56) 55 (47–61) 55 (49–58)
66 14†
59 50
8–1064) 801 (684–900) 888§ (799–985)
0–130) 110 (100–120) 110* (110–120)
–80) 70 (70–75) 73* (70–80)
–37) 25 (20–28) 28‡ (24–34)
–59) 61 (55–69) 58* (50–63)
–72) 71 (66–80) 70 (64–75)
41 19§
–21) 13 (11–15) 17† (14–20)
33) 21 (6–86) 16 (3–67)
40 50
–137) 72 (47–100) 92§ (69–112)
–52) 53 (46–75) 41† (37–51)
2–1.22) 1.22 (1.07–1.38) 1.10* (1.00–1.27)
9–142) 139 (137–141) 141† (139–143)
–4.5) 4.4 (4.2–4.7) 4.3* (4.1–4.5)
2–0.81) 0.88 (0.59–1.23) 0.67§ (0.45–0.87)
–12.3) 0.9 (0.1–2.0) 6.9† (4.5–9.8)ated
ment
p
0
0
0
0ith B
Acco
Untre
rs
s/mm
3* (47
11†
38
2‡ (85
5* (11
70 (70
3‡ (25
3‡ (47
7‡ (61
11†
7§ (14
7 (2–
23*
0† (86
5‡ (37
1* (0.9
41 (13
.4 (4.1
66 (0.5
9† (5.0 0.01, versus BRS 3 ms/mm Hg.
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January 13, 2009:193–9 Baroreceptors and Beta-Blockers in HFodification of autonomic dysfunction by beta-blockade
oes not affect the predictive value of BRS.
RS and beta-blockade. The ability of beta-blockade to
ncrease BRS in different patient populations, independent
f the particular beta-blocker used, is well known (10,11).
owever, differences have been observed between nonselec-
ive versus beta-1 selective blockade on cardiac norepineph-
ine spillover (CNES) in HF patients (12). We could not
ifferentiate between different beta-blockers in our study, as
0 of 103 patients were treated with the nonselective agent
arvedilol.
Mechanisms by which beta-blockade might increase BRS
n HF are poorly understood. Both hemodynamically me-
iated effects and direct effects related to beta-
drenoreceptor blockade are likely to be involved. Changes
n systolic function and in carotid pressure could be respon-
ible, at least in part, for the improvement in baroreflex
unction.
Complex interactions do occur between the sympathetic
nd the renin-angiotensin system in HF. Compelling phys-
ologic arguments and experimental data suggest that beta-
drenergic blockade may inhibit renin secretion, thereby
ontributing to the overall benefits of such interventions (2).
In a case-control study in 19 patients with HF (8), it was
ound that 4-month beta-blockade decreased CNES and
ncreased BRS vagal control of heart rate but had no
ignificant effect on muscle sympathetic nerve activity
MSNA). Higher BRS was correlated with lower CNES. A
ithdrawal of the inhibitory effects of excess cardiac nor-
esults From Multiple Regression Analysiss essing the Association Between Clinical andunctio al Covariates and RS
Table 4
Results From Multiple Regression Analysis
Assessing the Association Between Clinical and
Functional Covariates and BRS
Variable
Parameter
Estimate F Value p Value
Patients Receiving Beta-Blocker Treatment (n  103)
Intercept 7.35 8.29 0.005
LVEDD 0.012 7.65 0.007
Baseline RR interval 0.0005 3.11 0.081
VO2 peak 0.018 4.14 0.045
SDNN 0.0041 8.69 0.004
VPCs 0.0008 5.05 0.027
BUN 0.0053 5.08 0.027
Sodium 0.036 4.04 0.047
Patients Not Receiving Beta-Blocker Treatment (n  144)
Intercept 2.724 28.55 0.0001
NYHA functional class III 0.266 14.86 0.0002
LVEDD 0.006 4.09 0.045
Baseline RR interval 0.0007 10.57 0.001
VPCs 0.0003 2.90 0.091
BUN 0.004 5.40 0.022
Potassium 0.126 2.15 0.144
NSVT 0.176 7.05 0.009
RS measurements were log-transformed before analysis.
Abbreviations as in Table 1.pinephrine release on vagal modulation of sino-atrial dis-harge, rather than an augmentation of afferent or central
omponents of the baroreflex arc, has been claimed as a
ikely explanation. However, the interpretation of this study
ight be questioned because the conclusion that beta-
lockers affected only heart rate control and not MSNA
ould be driven by the small number of subjects and because
SNA may not reflect reflex sympathetic outflow to other
mportant areas such as the kidneys. Indeed, recent data (13)
upport a direct central sympatho-inhibitory effect of beta-
lockade.
linical correlates of BRS. These results confirm and
xtend our early findings (4) on the relationship between
RS and clinical and functional deterioration.
To determine the extent to which BRS reflects the
resence (and degree) of the pathological substrate of HF,
e analyzed predictors of BRS in both the treated and
ntreated state. It is well recognized that “physiologic”
actors exert a major influence on BRS. In 1,134 healthy
olunteers, Kardos et al. (14) found that age, heart rate,
ystolic and diastolic blood pressure, sex, body mass index,
Figure 1 Survival Curves
Kaplan-Meier survival curves according to dichotomized baroreceptor-heart
rate reflex sensitivity (BRS) in patients (A) taking and (B) not taking beta-blockers.
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Baroreceptors and Beta-Blockers in HF January 13, 2009:193–9nd smoking were independent “physiologic” predictors of
RS, accounting for close to 50% of the interindividual
ariability. The majority of these “physiologic” factors were
lso taken into account in our regression analysis, which
ncluded “pathologic” determinants (NYHA functional
lass, LV function, and arrhythmias) strictly linked to the
egree of HF. Similarities and differences in the 2 models
redicting BRS in treated and untreated patients are note-
orthy. First, the models shared more than 50% of observed
ignificant predictors (4 of 7 variables in the 2 models are
he same). Besides LV function and ventricular arrhythmias,
he association with BUN was not affected by beta-
lockade, thus focusing on the meaningful role of dimin-
shed renal function in HF (15). Moreover, it is of interest
hat NYHA functional class, the most important indepen-
ent predictor in untreated patients, was no longer a
redictor of BRS in treated patients (p  0.45). The
elationship between BRS and baseline RR interval (14)
eemed to have been blunted by the beta-blocker treatment,
ecause although the significance remained in the multivar-
ate model, it was only borderline compared with the
Demographic, Clinical, and Functional CharacteAccording to Card ac Mortality in the Entire Pop
Table 5 Demographic, Clinical, and FunctionAccording to Cardiac Mortality in th
Characteristic Alive
Age (yrs) 54
NYHA functional class III (%)
Ischemic etiology (%)
Baseline RR interval (ms) 878
Resting systolic arterial pressure (mm Hg) 110
Resting diastolic arterial pressure (mm Hg) 70
LVEF (%) 28
LVESD (mm) 57
LVEDD (mm) 68
Mitral regurgitation 2–3 (%)
Peak VO2 (ml/kg/min) 15
VPCs (n/h) 9
NSVT (%)
SDNN (ms) 92
BUN (mg/dl) 46
Creatinine (mg/dl) 1.13
Potassium (mEq/l) 4.4
Sodium (mEq/l) 141
Bilirubin (mg/dl) 0.69
BRS (ms/mm Hg) 4.3
Abbreviations as in Table 1.
esults of Cox Proportional Hazardsultivariate Reg ession Analysis (n  247)
Table 6 Results of Cox Proportional HazardsMultivariate Regression Analysis (n  247)
Chi-Square p Value Hazard Ratio 95% CI
BRS 3 10.32 0.0013 3.00 1.54–5.89
LVEDD 12.29 0.0005 1.04 1.02–1.08
BUN 4.61 0.032 1.01 1.00–1.02
Beta-blocker 7.81 0.005 0.23 0.08–0.64
Beta-blocker*BRS 0.25 0.62 1.37 0.40–4.72s
eta-blocker*BRS  interaction between beta-blocker and BRS.
CI  confidence interval; other abbreviations as in Table 1.ntreated state (Table 4). This is particularly relevant, as it
as been questioned (16) whether the “intrinsic” autonomic
ffect of a drug with a marked potential to slow heart rate,
hen assessed without adjusting for the heart rate change,
ay be artificially overestimated because of bradycardia . All
he variables listed in Table 4 accounted for 50% of the
nterindividual variation in BRS, thus providing a limited
xplanation of the wide scatter of BRS in our population of
F patients. Other factors not included in the present
nalysis (e.g., right atrial pressure, pulmonary pressures, and
o on) would likely have increased the model’s predictive
bility. By contrast, the intriguing possibility that the
utonomic balance may be influenced by genetic factors (17)
eserves consideration in future studies. Another factor
difficult to quantify) is the reduction in BRS resulting from
rousal or anxiety (18).
rognostic value. The prognostic value of BRS was well
stablished in an era when the use of beta-blockade in HF
as very uncommon. In 282 patients studied between 1992
nd 1996 (beta-blocker treatment 10%), we demonstrated
4) that in a multivariate model including NYHA functional
lass, peak VO2, LVEF, and mean 24-h RR interval, BRS
rovided independent prognostic information. We have
xtended these observations by comparing patients who
ere receiving beta-blockers at the time of BRS assessment
nd continued during follow-up with those who were never
reated over the study period. The prevalence of a depressed
RS nearly doubled among untreated patients (31% vs.
4%). In a multivariate analysis considering age, etiology,
YHA functional class, SAP, LVEF, LVEDD, BUN,
son
haracteristics
tire Population
175) Deceased (n  72) p Value
) 56 (49–61) 0.01
51 0.003
55 0.33
,015) 856 (750–946) 0.16
25) 110 (100–120) 0.46
) 70 (70–75) 0.11
) 25 (22–29) 0.005
) 62 (55–69) 0.0009
) 72 (67–81) 0.003
38 0.06
) 14 (12–17) 0.04
31 (10–105) 0.0001
44 0.19
5) 80 (61–102) 0.13
) 53 (46–66) 0.0001
1.27) 1.2 (1.09–1.38) 0.002
.6) 4.4 (4.3–4.7) 0.25
42) 140 (138–141) 0.04
0.93) 0.81 (0.66–1.10) 0.004
.3) 1.6 (0.3–3.0) 0.0001risticulati
al C
e En
(n 
(47–57
31
49
(778–1
(100–1
(70–80
(23–34
(50–64
(63–74
25
(13–19
(2–48)
35
(64–11
(38–54
(1.00–
(4.1–4
(139–1
(0.49–
(1.5–8erum sodium, peak VO2, SDNN, and ventricular arrhyth-
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January 13, 2009:193–9 Baroreceptors and Beta-Blockers in HFias as potential risk factors, and testing the interaction
etween beta-blockers and BRS, BRS was significantly
ssociated with a poor outcome, with an adjusted hazard
atio of 3.0 (95% CI: 1.54 to 5.89) (Table 6).
These results support the importance of renal dysfunction
n patients with HF (15) by showing that both BRS and
UN were independent predictors. It is noteworthy that
RS significantly predicted cardiac mortality in patients
ith chronic renal failure (19).
Specific aspects of the association between BRS and
ortality among treated patients deserve comment. In
atients with depressed BRS, baseline RR interval was
ignificantly lower, and these patients were also in worse
linical status, thus raising the possibility that a beta-blocker
as used to a lesser extent. However, this was not the case,
s the median dosage of the drug was not different in the 2
roups with preserved and depressed BRS (data not shown).
atients with depressed BRS may respond less than opti-
ally to a beta-blocker or may require higher doses to offset
he risk associated with a depressed BRS. Variability in the
esponse to a beta-blocker may also be responsible for the
ifference in BRS and in prognosis. A recent study (20)
uggests that specific genotypes are associated with survival
enefits and improved LVEF. Studies are needed on the
orrelation between beta-adrenoreceptor polymorphisms
nd BRS.
tudy limitations. A possible limitation of this study is the
elatively small sample size of treated patients and the
etrospective analysis. However, the study was carried out
n a prospectively collected database, and the patients were
ncluded only if they had BRS testing after adequate
eta-blocker titration.
onclusions
his study shows that BRS testing remains a valid tool in
F patients during treatment with beta-blockade. Clinical
nd functional variables independently related to BRS
xplained 50% of the variability of BRS in both treated
nd untreated patients, thus suggesting that BRS does not
imply mirror the pathophysiological substrate of HF. The
eversal of autonomic dysfunction brought about by beta-
lockade did not alter the predictive value of BRS. Accord-
ngly, a depressed BRS remains a significant predictor of
dverse prognosis in HF in the beta-blocker era.
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